Tozorakimab Notches Third Phase III Win in COPD
- AstraZeneca reported full results from two Phase III trials, OBERON and TITANIA, testing tozorakimab, an anti-IL-33 monoclonal antibody, added to standard inhaled therapy for chronic obstructive pulmonary disease (COPD).
- Across both trials, tozorakimab substantially cut moderate-to-severe exacerbation rates versus placebo in former smokers, with meaningful reductions also seen in a broader population including current smokers.
- The antibody is engineered to engage two separate IL-33 signaling pathways at once, a mechanism AstraZeneca positions as differentiating it from earlier single-pathway IL-33 drugs.
- This marks tozorakimab's third positive Phase III readout; results were presented at the European Respiratory Society Congress in Barcelona and published simultaneously in the New England Journal of Medicine.
- AstraZeneca is targeting US regulatory approval, expected in early 2027.
Three-for-three in Phase III is the real headline here — a track record like that de-risks tozorakimab in a way single-pathway IL-33 rivals (think itepekimab, astegolimab) can't yet match, strengthening AstraZeneca's hand with regulators and payers alike. The dual-pathway engineering pitch is the commercial wedge: as COPD biologics get crowded, "we hit both arms of IL-33 signaling" is a differentiation story sales teams can actually use. Strategically, this is AstraZeneca building a respiratory biologics franchise in a market that's long been underserved beyond inhalers — COPD's patient pool dwarfs severe asthma's. And running NEJM publication simultaneously with the ERS presentation isn't routine; it's a credibility move, front-loading peer-reviewed validation well ahead of the 2027 filing to pre-empt scrutiny.
AstraZeneca's faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win ↗